Arcutis insider plans $956K stock sale

Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran intends to sell restricted common stock through Merrill Lynch.

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran intends to sell restricted common stock through Merrill Lynch. The notice covers 38,200 shares of common stock with an aggregate market value of $956,124.61, expected to be sold on or after August 27, 2026 on NASDAQ.

The shares relate to stock option exercises on May 31, 2023 for 11,148 shares and June 14, 2024 for 27,052 shares. In the preceding three months, Terrie Curran sold 1,072 shares of common stock for $27,912.35.

Key Figures

Shares to be sold under Rule 144: 38,200 shares Aggregate market value of shares to be sold: $956,124.61 Proposed sale date: August 27, 2026 +4 more

7 metrics

Shares to be sold under Rule 144 38,200 shares Common stock proposed for sale through Merrill Lynch

Aggregate market value of shares to be sold $956,124.61 Value of 38,200 common shares covered by the notice

Proposed sale date August 27, 2026 Expected sale date for covered common stock on NASDAQ

Stock option exercise shares (2023) 11,148 shares Common stock from stock option exercise on May 31, 2023

Stock option exercise shares (2024) 27,052 shares Common stock from stock option exercise on June 14, 2024

Shares sold in past 3 months 1,072 shares Common stock sold on August 20, 2026

Proceeds from recent sale $27,912.35 Value received for 1,072 shares sold on August 20, 2026

Key Terms

Rule 144, Stock Option Exercise, Form 144

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 05/31/2023 | Stock Option Exercise | Arcutis Biotherapeutics"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Arcutis Biotherapeutics (ARQT)?

It discloses that Terrie Curran has filed a notice of proposed sale under Rule 144 for up to 38,200 shares of Arcutis Biotherapeutics common stock, with an aggregate market value of $956,124.61, expected to be sold on or after August 27, 2026 on NASDAQ.

How many ARQT shares are proposed to be sold under this Rule 144 notice?

The notice covers a proposed sale of 38,200 shares of Arcutis Biotherapeutics common stock. These shares are to be sold through Merrill Lynch and are associated with prior stock option exercises by Terrie Curran.

What is the aggregate market value of the ARQT shares covered by this Form 144?

The aggregate market value of the Arcutis Biotherapeutics shares covered by the notice is $956,124.61. This value applies to the 38,200 shares of common stock proposed to be sold under Rule 144.

When are the ARQT shares expected to be sold under this Form 144?

The proposed sale date for the covered Arcutis Biotherapeutics shares is August 27, 2026. The notice indicates these common shares are expected to be sold on or after that date on NASDAQ through Merrill Lynch.

What prior transactions by Terrie Curran in ARQT stock are disclosed?

The filing notes a sale on August 20, 2026 of 1,072 shares of Arcutis Biotherapeutics common stock for $27,912.35, and that the shares to be sold derive from stock option exercises on May 31, 2023 and June 14, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:07 PM EDT Accepted by SEC EDGAR 08/27/2026 - 04:05 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001690298
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Terrie Curran
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	38200	956124.61	125691961	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			11148	08/27/2026	Cash
Common	06/14/2024	Stock Option Exercise	Arcutis Biotherapeutics			27052	08/27/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Terrie Curran 3027 Towns Gate Rd Ste 300 Westlake Village CA 91361	Common	08/20/2026	1072	27912.35

144: Remarks and Signature

Remarks
Date of Notice	08/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Terrie Curran
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)